Skip to main content

Scientists Discover Way to Send Information into Black Holes Without Using Energy

3 comments

“100% Hair Regrowth?” Arthritis Drug Shows Remarkable Results in Severe Alopecia Areata Trials

For millions of people living with severe hair loss, a new treatment approach is offering fresh hope. An oral medicine originally developed to treat arthritis has shown significant potential for restoring scalp hair in people with severe alopecia areata, an autoimmune condition in which the body's immune system mistakenly attacks hair follicles.

In two international clinical trials, researchers found that upadacitinib, a once-daily immune-modulating drug, produced substantial hair regrowth in many participants. Some patients experienced near-complete or even complete restoration of scalp hair during the studies.

The findings are particularly important because the participants had already experienced extensive hair loss, making significant regrowth difficult to achieve with many existing approaches.

What Is Alopecia Areata?

Alopecia areata is an autoimmune disorder that causes the immune system to attack healthy hair follicles. As a result, hair suddenly begins falling out.

The condition does not affect everyone in the same way. Some people develop only a few small, round patches of hair loss, while others can lose most or all of their scalp hair. In more severe cases, eyebrows, eyelashes and hair across the body may also be affected.

For people with extensive and long-lasting alopecia areata, finding an effective treatment can be particularly challenging.

Researchers have increasingly focused on the immune mechanisms responsible for the disease rather than simply trying to stimulate hair growth.

Why an Arthritis Drug Could Help Hair Grow

Upadacitinib belongs to a class of medicines known as Janus kinase, or JAK, inhibitors.

JAK proteins are involved in transmitting signals that help regulate the body's immune and inflammatory responses. In alopecia areata, certain immune signals contribute to the attack on hair follicles.

The idea behind using a JAK inhibitor is relatively straightforward: if researchers can block some of these immune signals, they may be able to reduce the attack on the hair follicles and allow them to return to their normal hair-producing cycle.

This means the treatment is not simply attempting to force hair follicles to grow. Instead, it aims to address an important part of the underlying autoimmune process.

International Clinical Trials

The two trials involved medical centers across multiple regions, including North America, Europe and China.

Researchers studied people with severe alopecia areata who had experienced substantial scalp hair loss. On average, participants had lost approximately 84% of their scalp hair before entering the trials.

Participants were randomly assigned to receive either 15 milligrams or 30 milligrams of upadacitinib, or a placebo, once a day.

The researchers then monitored their scalp hair coverage over the course of treatment.

Some participants had also experienced persistent hair loss for significant periods, making the observed regrowth particularly notable.

Major Hair Regrowth Seen After 24 Weeks

The results, published on August 12 in JAMA Dermatology, showed that patients receiving upadacitinib experienced substantially greater hair regrowth than those receiving placebo treatment.

After approximately 24 weeks, around half of the patients receiving either dose achieved at least 80% scalp hair coverage.

Some participants went even further, experiencing near-complete or complete scalp hair regrowth.

For someone who had previously lost most of their scalp hair, reaching this level of coverage represents a major change.

However, the results should not be interpreted as meaning that everyone taking the drug will regain 100% of their hair.

The response varied from person to person. Some participants experienced more extensive regrowth than others, while the speed of improvement also differed.

Why the Findings Matter

The significance of the research goes beyond the percentage of hair that grew back.

Many people with severe alopecia areata face long-term physical and emotional challenges. Extensive hair loss can affect appearance, confidence and everyday social experiences.

The new findings suggest that controlling the immune response may allow damaged or disrupted hair follicles to resume producing hair.

The results also demonstrate how medicines developed for one disease can sometimes find applications in completely different medical conditions when researchers understand the biological pathways involved.

Upadacitinib is already used to treat several inflammatory diseases, including rheumatoid arthritis. Its existing clinical history means researchers already have considerable information about how the medicine works and its potential risks.

Nevertheless, using an established medicine for a new condition still requires careful evaluation.

Complete Regrowth Does Not Mean a Permanent Cure

One of the most important questions now is whether the hair regrowth can be maintained over the long term.

Alopecia areata is an autoimmune disease, meaning the underlying immune tendency can remain even when hair begins to grow again.

Researchers therefore need longer follow-up to determine whether patients can maintain their regrowth while continuing treatment and what happens after treatment is reduced or stopped.

Safety is another important consideration.

Because JAK inhibitors modify immune activity, they can have significant side effects and are not suitable for everyone. Their use requires medical supervision, and doctors must carefully consider an individual's health history and risk factors.

Therefore, these findings should be viewed as promising clinical evidence—not as proof that upadacitinib is a guaranteed cure for alopecia areata.

A Potential New Direction for Hair-Loss Treatment

The research highlights an important change in how scientists are approaching severe hair loss.

Instead of focusing only on the hair follicle itself, researchers are increasingly investigating the immune system signals that cause the follicle to stop functioning normally.

If these signals can be controlled safely, the hair follicle may have an opportunity to recover.

The upadacitinib trials provide encouraging evidence that this strategy can produce substantial hair regrowth in people who had previously lost most of their scalp hair.

Still, more research will be needed to understand who benefits most, how long the results last, and how the treatment's benefits compare with its potential risks.

For now, the findings represent a significant development in the search for better treatments for severe alopecia areata.

The idea that an immune-targeting medicine originally developed for arthritis could help restore hair demonstrates just how closely different areas of medicine can be connected—and it could open the door to even more targeted treatments for autoimmune hair loss in the future.

Reference: Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials. JAMA Dermatol. Published online August 12, 2026. doi:10.1001/jamadermatol.2026.2853

Comments

Post a Comment

Popular

Scientists Discover Way to Send Information into Black Holes Without Using Energy

For years, scientists believed that adding even one qubit (a unit of quantum information) to a black hole needed energy. This was based on the idea that a black hole’s entropy must increase with more information, which means it must gain energy. But a new study by Jonah Kudler-Flam and Geoff Penington changes that thinking. They found that quantum information can be teleported into a black hole without adding energy or increasing entropy . This works through a process called black hole decoherence , where “soft” radiation — very low-energy signals — carry information into the black hole. In their method, the qubit enters the black hole while a new pair of entangled particles (like Hawking radiation) is created. This keeps the total information balanced, so there's no violation of the laws of physics. The energy cost only shows up when information is erased from the outside — these are called zerobits . According to Landauer’s principle, erasing information always needs energy. But ...
3 comments
Read more

A New Type of Wormhole Could Slowly Become Stable Over Time, Scientists Suggest

For many years, wormholes have captured the imagination of scientists and science fiction fans. They are often shown as magical tunnels through space that can connect two faraway places in the universe. If wormholes really exist, they could one day make it possible to travel huge distances in a very short time. But there is one big problem—no one has ever found a real wormhole. They remain only theoretical objects predicted by the mathematics of Einstein's theory of general relativity. Even though they have never been observed, physicists continue studying them because they help us understand the limits of gravity and spacetime. Now, researchers Ditta and Channuie have proposed a new model of a time-dependent traversable wormhole . Unlike many earlier models, their wormhole is not completely still. Instead, it changes with time because energy flows through it. As this flow slowly fades away, the wormhole naturally becomes stable. Their study offers a new and simple way to understan...
Post a Comment
Read more

Black Holes That Never Dies

Black holes are powerful objects in space with gravity so strong that nothing can escape them. In the 1970s, Stephen Hawking showed that black holes can slowly lose energy by giving off tiny particles. This process is called Hawking radiation . Over time, the black hole gets smaller and hotter, and in the end, it disappears completely. But new research by Menezes and his team shows something different. Using a theory called Loop Quantum Gravity (LQG) , they studied black holes with quantum corrections. In their model, the black hole does not vanish completely. Instead, it stops shrinking when it reaches a very small size. This leftover is called a black hole remnant . They also studied something called grey-body factors , which affect how much energy escapes from a black hole. Their findings show that the black hole cools down and stops losing mass once it reaches a minimum mass . This new model removes the idea of a “singularity” at the center of the black hole and gives us a better ...
Post a Comment
Read more